Fig. 8: Changes in ferroptosis-related characteristics of prostate cancer cells treated with Betulin and the synergistic therapeutic effect of Betulin and docetaxel.
From: SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance
A Intracellular ferrous ion staining was performed using the ferrous ion probe FerroOrange, and cell nuclei were stained using DAPI (n = 3). B Quantification of ferrous iron staining. C Intracellular mitochondrial membrane potential staining, using JC-1 staining, aggregates are in red, and monomers are in green (n = 3). D Quantification of JC-1 staining, results were shown as the ratio of aggregates to monomers. E Heat map of cell activity, with the horizontal axis representing the betulin treatment concentration and the vertical axis representing the docetaxel treatment concentration (n = 5). F Heat map of drug combination synergistic effects, presented as the analysis results of the zero interaction potency (ZIP) model, completed by SynergyFinder. G 3D heat map of drug combination synergy, presented as the analysis result of zero interaction potency (ZIP) model, completed by SynergyFinder. ZIP zero interaction potency (ZIP). Data were presented as mean ± SD. (ns, P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
